-
10
-
-
0019997481
-
-
Nishitani T., Horikawa H., Iwasaki T., Matsumoto K., Inoue I., and Miyoshi M. J. Org. Chem. 47 (1982) 1706-1712
-
(1982)
J. Org. Chem.
, vol.47
, pp. 1706-1712
-
-
Nishitani, T.1
Horikawa, H.2
Iwasaki, T.3
Matsumoto, K.4
Inoue, I.5
Miyoshi, M.6
-
14
-
-
34548510534
-
-
For examples of the pyrrolidin-2-yl analogues, see:
-
-
-
-
20
-
-
34548471707
-
-
For examples of the pyrrolidin-3-yl analogues, see:
-
-
-
-
25
-
-
0035830519
-
-
Püschl A., Boesen T., Zuccarello G., Dahl O., Pitsch S., and Nielsen P.E. J. Org. Chem. 66 (2001) 707-712
-
(2001)
J. Org. Chem.
, vol.66
, pp. 707-712
-
-
Püschl, A.1
Boesen, T.2
Zuccarello, G.3
Dahl, O.4
Pitsch, S.5
Nielsen, P.E.6
-
27
-
-
0034700188
-
-
Hickman D.T., King P.M., Cooper M.A., Slater J.M., and Mickelfield J. Chem. Commun. (2000) 2251-2252
-
(2000)
Chem. Commun.
, pp. 2251-2252
-
-
Hickman, D.T.1
King, P.M.2
Cooper, M.A.3
Slater, J.M.4
Mickelfield, J.5
-
28
-
-
34548509396
-
-
For examples of the pyrrolidin-1-yl analogues, see:
-
-
-
-
35
-
-
33748704420
-
-
Zheltonogova E.A., Oleneva G.I., Shapovalenko E.P., Belavin I.Yu., Shipov A.G., and Baukov Yu.I. J. Gen. Chem. USSR 60 (1990) 1245-1249
-
(1990)
J. Gen. Chem. USSR
, vol.60
, pp. 1245-1249
-
-
Zheltonogova, E.A.1
Oleneva, G.I.2
Shapovalenko, E.P.3
Belavin, I.Yu.4
Shipov, A.G.5
Baukov, Yu.I.6
-
36
-
-
0346672993
-
-
( )
-
(. Zh. Obshch. Khim. 60 (1990) 1390-1395 )
-
(1990)
Zh. Obshch. Khim.
, vol.60
, pp. 1390-1395
-
-
-
37
-
-
0036181648
-
-
Chmielewski J., Huan M., Topmiller K., Ward J., and Church K.M. Synth. Commun. 32 (2002) 343-353
-
(2002)
Synth. Commun.
, vol.32
, pp. 343-353
-
-
Chmielewski, J.1
Huan, M.2
Topmiller, K.3
Ward, J.4
Church, K.M.5
-
40
-
-
0028905327
-
-
Wong C.-H., Provencher L., Porco J.A., Jung S.-H., Wang Y.-F., Chen L., Wang R., and Steensma D.H. J. Org. Chem. 60 (1995) 1492-1501
-
(1995)
J. Org. Chem.
, vol.60
, pp. 1492-1501
-
-
Wong, C.-H.1
Provencher, L.2
Porco, J.A.3
Jung, S.-H.4
Wang, Y.-F.5
Chen, L.6
Wang, R.7
Steensma, D.H.8
-
45
-
-
0037926704
-
-
Yamasaki T., Abdel-Aziz M., Kiyota N., Maruyama T., and Otsuka M. Heterocycles 60 (2003) 1561-1566
-
(2003)
Heterocycles
, vol.60
, pp. 1561-1566
-
-
Yamasaki, T.1
Abdel-Aziz, M.2
Kiyota, N.3
Maruyama, T.4
Otsuka, M.5
-
50
-
-
0033168078
-
-
Atigadda V.R., Brouillette W.J., Duarte F., Ali S.M., Babu Y.S., Bantia S., Chand P., Chu N., Montgomery J.A., Walsh D.A., Sudbeck E.A., Finley J., Luo M., Air G.M., and Laver G.W. J. Med. Chem. 42 (1999) 2332-2343
-
(1999)
J. Med. Chem.
, vol.42
, pp. 2332-2343
-
-
Atigadda, V.R.1
Brouillette, W.J.2
Duarte, F.3
Ali, S.M.4
Babu, Y.S.5
Bantia, S.6
Chand, P.7
Chu, N.8
Montgomery, J.A.9
Walsh, D.A.10
Sudbeck, E.A.11
Finley, J.12
Luo, M.13
Air, G.M.14
Laver, G.W.15
-
52
-
-
0041419939
-
-
Anastasi C., Quelever G., Burlet S., Garino C., Souard F., and Kraus J.-L. Curr. Med. Chem. 10 (2003) 1825-1843
-
(2003)
Curr. Med. Chem.
, vol.10
, pp. 1825-1843
-
-
Anastasi, C.1
Quelever, G.2
Burlet, S.3
Garino, C.4
Souard, F.5
Kraus, J.-L.6
-
57
-
-
0038334973
-
-
Kang J.-H., Chung H.-E., Kim S.Y., Kim Y., Lee J., Lewin N.E., Pearce L.V., Blumberg P.M., and Marquez V.E. Bioorg. Med. Chem. 11 (2003) 2529-2540
-
(2003)
Bioorg. Med. Chem.
, vol.11
, pp. 2529-2540
-
-
Kang, J.-H.1
Chung, H.-E.2
Kim, S.Y.3
Kim, Y.4
Lee, J.5
Lewin, N.E.6
Pearce, L.V.7
Blumberg, P.M.8
Marquez, V.E.9
-
59
-
-
0028102858
-
-
Dueholm K.L., Egholm M., Behrens C., Christensen L., Hansen H.F., Vulpius T., Petersen K.H., Berg R.H., Nielsen P.E., and Buchardt O. J. Org. Chem. 59 (1994) 5767-5773
-
(1994)
J. Org. Chem.
, vol.59
, pp. 5767-5773
-
-
Dueholm, K.L.1
Egholm, M.2
Behrens, C.3
Christensen, L.4
Hansen, H.F.5
Vulpius, T.6
Petersen, K.H.7
Berg, R.H.8
Nielsen, P.E.9
Buchardt, O.10
-
63
-
-
4544232586
-
-
Tolle-Sander S., Lentz K.A., Maeda D.Y., Coop A., and Polli J.E. Mol. Pharmacol. 1 (2004) 40-48
-
(2004)
Mol. Pharmacol.
, vol.1
, pp. 40-48
-
-
Tolle-Sander, S.1
Lentz, K.A.2
Maeda, D.Y.3
Coop, A.4
Polli, J.E.5
-
64
-
-
34548495513
-
-
note
-
50) required to reduce virus-induced cytopathogenicity by 50%.
-
-
-
-
65
-
-
34548508617
-
-
note
-
The cytotoxicity was expressed as the minimum cytotoxic concentration (MCC) required to cause a microscopically detectable alteration of normal cell morphology.
-
-
-
-
66
-
-
34548498568
-
-
note
-
50 of 150 μM.
-
-
-
-
67
-
-
34548511036
-
-
note
-
50 of 0.0064 μM.
-
-
-
-
68
-
-
34548501479
-
-
note
-
The reference compounds displayed the following MCC values: brivudin and ribavirin (Vero, HEL or HeLa cells, >250 μM); (S)-DHPA (HeLa cells, >250 μM); acyclovir (HEL cells, >250 μM); ganciclovir (HEL cells, >100 μM).
-
-
-
-
69
-
-
34548509154
-
-
note
-
50) required to reduce virus plaque formation by 50%. Virus input was 100 plaque-forming units (PFU) for cytomegalovirus, or 20 PFU for varicella-zoster virus.
-
-
-
-
70
-
-
34548499024
-
-
note
-
50) required to reduce cell growth by 50%.
-
-
-
-
71
-
-
34548499263
-
-
note
-
50=257 μM.
-
-
-
-
72
-
-
0018819307
-
-
De Clercq E., Descamps J., Verhelst G., Walker R.T., Jones A.S., Torrence P.F., and Shugar D. J. Infect. Dis. 141 (1980) 563-574
-
(1980)
J. Infect. Dis.
, vol.141
, pp. 563-574
-
-
De Clercq, E.1
Descamps, J.2
Verhelst, G.3
Walker, R.T.4
Jones, A.S.5
Torrence, P.F.6
Shugar, D.7
-
73
-
-
0024407007
-
-
De Clercq E., Cools M., Balzarini J., Marquez V.E., Borcherding D.R., Borchardt R.T., Drach J.C., Kitaoka S., and Konno T. Antimicrob. Agents Chemother. 33 (1989) 1291-1297
-
(1989)
Antimicrob. Agents Chemother.
, vol.33
, pp. 1291-1297
-
-
De Clercq, E.1
Cools, M.2
Balzarini, J.3
Marquez, V.E.4
Borcherding, D.R.5
Borchardt, R.T.6
Drach, J.C.7
Kitaoka, S.8
Konno, T.9
|